Haemonetics (HAE)
Market Price (8/19/2026): $104.5 | Market Cap: $4.7 BilSector: Health Care | Industry: Health Care Supplies
Haemonetics (HAE)
Market Price (8/19/2026): $104.5Market Cap: $4.7 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 22% Attractive yieldFCF Yield is 7.1% Low stock price volatilityVol 12M is 47% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, and Automation & Robotics. Themes include Geriatric Care, Show more. | Trading close to highsDist 52W High is -1.2% Weak multi-year price returns2Y Excs Rtn is -24%, 3Y Excs Rtn is -74% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/EPrice/Earnings or Price/(Net Income) is 43x Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% Key risksHAE key risks include [1] mounting competitive pressure on its VASCADE devices from specific rival products and [2] significant customer concentration in its vital plasma business, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 22% |
| Attractive yieldFCF Yield is 7.1% |
| Low stock price volatilityVol 12M is 47% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, and Automation & Robotics. Themes include Geriatric Care, Show more. |
| Trading close to highsDist 52W High is -1.2% |
| Weak multi-year price returns2Y Excs Rtn is -24%, 3Y Excs Rtn is -74% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/EPrice/Earnings or Price/(Net Income) is 43x |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% |
| Key risksHAE key risks include [1] mounting competitive pressure on its VASCADE devices from specific rival products and [2] significant customer concentration in its vital plasma business, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Haemonetics (HAE) stock has gained about 75% since 4/30/2026 because of the following key factors:
1. Exceptional Fiscal Q1 2027 Performance and Upgraded Outlook.
Haemonetics reported strong fiscal Q1 2027 results, which ended in June 2026, significantly exceeding analyst expectations. The company announced an adjusted EPS of $1.14, substantially beating the Wall Street consensus of $0.87. Additionally, net revenue reached $339.4 million, surpassing the $327.9 million consensus. Following this strong performance, management raised its fiscal year 2027 revenue and adjusted EPS growth guidance to 5%-8% from the previous 4%-7% outlook.
2. Strategic Supply Agreement with CSL Plasma.
Haemonetics announced a significant supply agreement with CSL Plasma Inc. on August 14, 2026, enabling CSL to adopt Haemonetics' NexSys PCS devices with Persona PLUS technology across its U.S. network. This news was a major catalyst, driving shares up by 9% in pre-market trading on August 18, 2026, and is expected to bolster the plasma segment by expanding market access and revenue streams.
Show more
Haemonetics (HAE) stock has gained about 75% since 4/30/2026 because of the following key factors:
1. Exceptional Fiscal Q1 2027 Performance and Upgraded Outlook.
Haemonetics reported strong fiscal Q1 2027 results, which ended in June 2026, significantly exceeding analyst expectations. The company announced an adjusted EPS of $1.14, substantially beating the Wall Street consensus of $0.87. Additionally, net revenue reached $339.4 million, surpassing the $327.9 million consensus. Following this strong performance, management raised its fiscal year 2027 revenue and adjusted EPS growth guidance to 5%-8% from the previous 4%-7% outlook.
2. Strategic Supply Agreement with CSL Plasma.
Haemonetics announced a significant supply agreement with CSL Plasma Inc. on August 14, 2026, enabling CSL to adopt Haemonetics' NexSys PCS devices with Persona PLUS technology across its U.S. network. This news was a major catalyst, driving shares up by 9% in pre-market trading on August 18, 2026, and is expected to bolster the plasma segment by expanding market access and revenue streams.
3. Numerous Analyst Upgrades and Price Target Increases.
Following the robust fiscal Q1 2027 earnings and the CSL Plasma deal, several prominent analysts increased their price targets and reiterated positive ratings for HAE. Bank of America raised its price target to $100 from $93 with a Buy rating, while Raymond James increased its target to $105 and maintained an Outperform rating. BTIG also raised its price target from $96 to $110, maintaining a Buy rating.
4. Sustained Growth Across Key Business Segments.
Haemonetics demonstrated broad-based demand and growth across its core businesses in fiscal Q1 2027, with the Plasma, Blood Management Technologies, and Interventional Technologies segments all contributing positively. Plasma revenue increased by 7.2% year-over-year, with 8.2% organic growth. Blood Management Technologies revenue grew by 8.6% year-over-year (8.1% organic growth), and Interventional Technologies revenue saw a 2.5% year-over-year increase, including 2.8% organic growth, indicating a return to growth for this segment.
Show less
Stock Movement Drivers
Fundamental Drivers
The 74.2% change in HAE stock from 4/30/2026 to 8/18/2026 was primarily driven by a 207.6% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 60.09 | 104.65 | 74.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,318 | 1,352 | 2.6% |
| Net Income Margin (%) | 13.3% | 7.1% | -46.5% |
| P/E Multiple | 16.0 | 49.3 | 207.6% |
| Shares Outstanding (Mil) | 47 | 45 | 3.2% |
| Cumulative Contribution | 74.2% |
Market Drivers
4/30/2026 to 8/18/2026| Return | Correlation | |
|---|---|---|
| HAE | 74.2% | |
| Market (SPY) | 6.8% | -5.6% |
| Sector (XLV) | 16.3% | 34.3% |
Fundamental Drivers
The 57.0% change in HAE stock from 1/31/2026 to 8/18/2026 was primarily driven by a 161.4% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 66.66 | 104.65 | 57.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,328 | 1,352 | 1.8% |
| Net Income Margin (%) | 12.7% | 7.1% | -43.8% |
| P/E Multiple | 18.9 | 49.3 | 161.4% |
| Shares Outstanding (Mil) | 48 | 45 | 4.9% |
| Cumulative Contribution | 57.0% |
Market Drivers
1/31/2026 to 8/18/2026| Return | Correlation | |
|---|---|---|
| HAE | 57.0% | |
| Market (SPY) | 11.2% | 2.7% |
| Sector (XLV) | 10.1% | 29.1% |
Fundamental Drivers
The 41.3% change in HAE stock from 7/31/2025 to 8/18/2026 was primarily driven by a 127.0% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 74.04 | 104.65 | 41.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,361 | 1,352 | -0.6% |
| Net Income Margin (%) | 12.3% | 7.1% | -42.2% |
| P/E Multiple | 21.7 | 49.3 | 127.0% |
| Shares Outstanding (Mil) | 49 | 45 | 8.4% |
| Cumulative Contribution | 41.3% |
Market Drivers
7/31/2025 to 8/18/2026| Return | Correlation | |
|---|---|---|
| HAE | 41.3% | |
| Market (SPY) | 22.4% | 3.3% |
| Sector (XLV) | 31.8% | 25.7% |
Fundamental Drivers
The 13.5% change in HAE stock from 7/31/2023 to 8/18/2026 was primarily driven by a 22.3% change in the company's P/E Multiple.| (LTM values as of) | 7312023 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 92.24 | 104.65 | 13.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,169 | 1,352 | 15.7% |
| Net Income Margin (%) | 9.9% | 7.1% | -27.9% |
| P/E Multiple | 40.3 | 49.3 | 22.3% |
| Shares Outstanding (Mil) | 50 | 45 | 11.2% |
| Cumulative Contribution | 13.5% |
Market Drivers
7/31/2023 to 8/18/2026| Return | Correlation | |
|---|---|---|
| HAE | 13.5% | |
| Market (SPY) | 73.6% | 21.7% |
| Sector (XLV) | 32.5% | 29.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HAE Return | -55% | 48% | 9% | -9% | 3% | 13% | -24% |
| Peers Return | 9% | -25% | -12% | 4% | 1% | 23% | -9% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| HAE Win Rate | 42% | 67% | 58% | 42% | 33% | 62% | |
| Peers Win Rate | 45% | 38% | 42% | 48% | 47% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HAE Max Drawdown | -64% | -23% | -18% | -27% | -40% | -38% | |
| Peers Max Drawdown | -17% | -38% | -34% | -21% | -34% | -25% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ICUI, LIVN, BAX, BDX, MDT. See HAE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/18/2026 (YTD)
How Low Can It Go
| Event | HAE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -12.0% | -18.8% |
| % Gain to Breakeven | 13.6% | 23.1% |
| Time to Breakeven | 21 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -16.0% | -7.8% |
| % Gain to Breakeven | 19.0% | 8.5% |
| Time to Breakeven | 86 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -12.2% | -9.5% |
| % Gain to Breakeven | 13.9% | 10.5% |
| Time to Breakeven | 153 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.0% | -24.5% |
| % Gain to Breakeven | 25.0% | 32.4% |
| Time to Breakeven | 13 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -38.3% | -33.7% |
| % Gain to Breakeven | 62.0% | 50.9% |
| Time to Breakeven | 294 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -19.2% | -19.2% |
| % Gain to Breakeven | 23.8% | 23.8% |
| Time to Breakeven | 175 days | 105 days |
In The Past
Haemonetics's stock fell -12.0% during the 2025 US Tariff Shock. Such a loss loss requires a 13.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | HAE | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -38.3% | -33.7% |
| % Gain to Breakeven | 62.0% | 50.9% |
| Time to Breakeven | 294 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -24.6% | -12.2% |
| % Gain to Breakeven | 32.6% | 13.9% |
| Time to Breakeven | 309 days | 62 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -21.0% | -53.4% |
| % Gain to Breakeven | 26.7% | 114.4% |
| Time to Breakeven | 101 days | 1085 days |
In The Past
Haemonetics's stock fell -12.0% during the 2025 US Tariff Shock. Such a loss loss requires a 13.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Haemonetics (HAE)
Haemonetics Corporation (HAE) is a global healthcare company that develops and provides a range of medical products and solutions primarily focused on blood and plasma management. The company's mission is to help healthcare professionals and organizations efficiently collect, process, and manage blood components and plasma, while also offering crucial diagnostic tools to enhance patient care and operational efficiency.
The company operates through three main segments. In its Plasma segment, Haemonetics offers automated plasma collection devices like NexSys PCS, along with associated disposables and integrated software platforms such as NexLynk DMS. These solutions enable plasma centers to streamline donor management, optimize operations, and manage their supply chain effectively. The Blood Center segment provides automated apheresis equipment (e.g., MCS brand) for collecting specific blood components, manual whole blood collection sets, and sophisticated software systems like SafeTrace Tx to manage donations, track blood units, and support donor recruitment and retention for blood banks.
Haemonetics' Hospital segment delivers critical products for patient care within hospital settings. This includes the TEG diagnostic systems, which allow clinicians to quickly assess a patient's coagulation status at the point-of-care or in the lab, supported by TEG Manager software for remote access. Additionally, the company offers the Cell Saver Elite+ for autologous blood recovery during surgeries and the BloodTrack suite, a comprehensive set of software and hardware solutions designed for advanced blood management and safe bedside transfusions. These hospital products serve clinicians, surgeons, and hospital blood banks, contributing to improved patient outcomes and operational efficiency in surgical, critical care, and general hospital environments.
```AI Analysis | Feedback
It's like BD (Becton, Dickinson and Company) for specialized blood and plasma collection and management solutions.
Think of it as a highly focused Thermo Fisher Scientific for blood and plasma processing, diagnostics, and patient care.
AI Analysis | Feedback
- NexSys PCS and PCS2: Automated plasmapheresis equipment and associated disposables for plasma collection.
- NexLynk DMS: An integrated information technology platform for managing plasma donors, operations, and supply chain.
- MCS brand apheresis equipment: Automated systems for collecting specific blood components from donors.
- Disposable whole blood collection and component storage sets: Products used for manual whole blood collection and storing blood components.
- SafeTrace Tx and El-Dorado Donor: Management systems for blood donations and blood units.
- TEG diagnostic systems: Point-of-care and laboratory systems that assess a patient's coagulation status.
- Cell Saver Elite +: An autologous blood recovery system used in various surgical procedures.
- BloodTrack: A suite of solutions combining software and hardware for blood management and bedside transfusion.
AI Analysis | Feedback
Haemonetics (HAE) primarily sells its products and solutions to other companies and organizations, rather than directly to individuals. The provided company description does not list the names of specific customer companies or their symbols.
However, based on the description of its three segments, Haemonetics' major customers fall into the following categories of organizational entities:
- Plasma Collection Companies/Centers: These customers utilize Haemonetics' automated plasma collection devices, related disposables, software, and IT platforms (e.g., NexSys PCS, NexLynk DMS) to manage donors, operations, and supply chains for plasma collection.
- Blood Centers and Blood Banks: Customers in this category use products such as automated blood component collection systems (e.g., MCS brand apheresis equipment), disposable whole blood collection and storage sets, and blood unit management software (e.g., SafeTrace Tx, Hemasphere) for donor management and blood processing.
- Hospitals and Clinical Laboratories: This segment's customers include hospitals and their associated laboratories, which use products like TEG diagnostic systems for coagulation assessment, Cell Saver Elite + for autologous blood recovery during surgery, and BloodTrack solutions for blood management and bedside transfusions.
AI Analysis | Feedback
AI Analysis | Feedback
Christopher Simon, President and Chief Executive Officer
Christopher Simon was appointed President and Chief Executive Officer of Haemonetics in May 2016. He brings over 30 years of experience in healthcare. Prior to joining Haemonetics, he served as a Senior Partner at McKinsey & Company, where he led the Global Medical Products Practice. Earlier in his career, he held commercial and operating roles at Baxter Healthcare Corporation and served as a U.S. Army Infantry Officer. Mr. Simon holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.
James C. D'Arecca, Executive Vice President, Chief Financial Officer
James C. D'Arecca joined Haemonetics as Executive Vice President, Chief Financial Officer in April 2022. He has nearly 30 years of experience in finance leadership and strategy. Before Haemonetics, Mr. D'Arecca was Chief Financial Officer of TherapeuticsMD, a women's healthcare company, from June 2020 to April 2022. He previously served as Senior Vice President and Chief Accounting Officer at Allergan plc (formerly Actavis plc) for nearly seven years until its merger with AbbVie Inc. in May 2020. His career also includes roles as Chief Accounting Officer at Bausch & Lomb and finance and business development positions at Merck & Co., Inc. and Schering-Plough. He began his career at PricewaterhouseCoopers, focusing on pharmaceuticals, medical devices, and consumer products. Mr. D'Arecca is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Rutgers University and an MBA from Columbia University.
Michelle L. Basil, Executive Vice President, General Counsel
Michelle L. Basil serves as the Executive Vice President, General Counsel of Haemonetics.
Frank W. Chan, Ph.D., Executive Vice President, Chief Operating Officer
Frank W. Chan, Ph.D. joined Haemonetics as Executive Vice President, Chief Operating Officer in April 2025. He has over 25 years of experience in medical device and healthcare technology leadership, including delivering innovative solutions to market and leading business transformation. Prior to Haemonetics, he was President of Acute Care & Monitoring at Medtronic plc and held various roles at Covidien plc (acquired by Medtronic) and DePuy Orthopaedics, Inc. (a Johnson & Johnson company).
Roy Galvin, Executive Vice President, Chief Commercial Officer
Roy Galvin was appointed Executive Vice President, Chief Commercial Officer in March 2025. He originally joined Haemonetics in 2022 as President, Global Plasma and Blood Center. In his expanded role, he is responsible for the company's Global Hospital business, as well as Global Plasma and Blood Center, overseeing all commercialization initiatives.
AI Analysis | Feedback
The key risks to Haemonetics' business are:
-
Dependence on Plasma and Blood Donation Volumes and Regulatory Changes: A significant portion of Haemonetics' revenue is derived from its Plasma and Blood Center segments, which are directly reliant on the volume of plasma and whole blood donations. Any factors that negatively impact donor availability, such as public health crises, changes in donor eligibility criteria, or shifts in societal attitudes towards donation, could reduce demand for their collection devices, disposables, and donor management systems. Additionally, changes in regulatory policies regarding plasma collection, blood safety, or donor compensation could significantly affect these core business segments.
-
Intense Competition and Rapid Technological Advancements: Haemonetics operates in highly competitive markets across its Plasma, Blood Center, and Hospital segments. The medical device and healthcare IT industries are characterized by continuous innovation and evolving technologies. Competitors may develop more advanced, efficient, or cost-effective collection systems, diagnostic tools, or blood management software. The company's ability to maintain and grow its market share depends on its capacity for ongoing research and development, successful product innovation, and effective differentiation from competitors.
-
Supply Chain Risks for Critical Disposables: Many of Haemonetics' products, including those for plasma collection, blood component separation, and surgical blood recovery (e.g., Cell Saver Elite+), utilize proprietary disposable components. Disruptions in the supply chain for these critical disposables, such as raw material shortages, manufacturing delays, or geopolitical events, could significantly impact the company's ability to supply its customers, fulfill orders, and generate recurring revenue. This reliance on a steady and reliable supply of disposables makes the company vulnerable to various supply chain challenges.
AI Analysis | Feedback
AI Analysis | Feedback
Haemonetics Corporation (HAE) operates in several key medical technology markets, providing products and solutions across plasma, blood center, and hospital segments. The addressable markets for its main products and services include:
-
Plasma Collection Devices and Related Disposables (e.g., NexSys PCS, PCS2 plasmapheresis equipment): These products fall under the broader Apheresis Equipment Market. The global apheresis equipment market size was valued at approximately USD 3.51 billion in 2025 and is projected to increase to about USD 8.39 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 9.11% from 2026 to 2035. North America held the largest share of this global market, accounting for 35% in 2025.
-
Automated Blood Component and Manual Whole Blood Collection Systems (e.g., MCS brand apheresis equipment, disposable whole blood collection sets): These products are part of the global Blood Collection Devices Market. This market was valued at USD 9.4 billion in 2025 and is projected to grow to USD 18.07 billion by 2034, at a CAGR of 7.53%. North America accounts for approximately 35% of the Blood Collection Devices Market.
-
TEG Diagnostic Systems: These are key components of the Thromboelastography Analyzer Market. The global thromboelastography analyzer market size was valued at USD 383 million in 2024 and is projected to reach USD 729 million by 2032, with a CAGR of 9.9%. North America dominates this market, holding a 37% share.
-
Cell Saver Elite+ (Autologous Blood Recovery System): This product is part of the Autotransfusion Systems Market. The global autotransfusion systems market size was over USD 534.6 million in 2025 and is estimated to reach USD 872.9 million by the end of 2035, growing at a CAGR of 5.6% during the forecast timeline. North America is projected to be the largest regional market, holding a 34.6% share by 2035.
-
BloodTrack (Blood Management and Bedside Transfusion Solutions): This falls under the Blood Management Software Market. This market was valued at USD 1.23 billion in 2025 and is estimated to grow to USD 2.05 billion by 2031, at a CAGR of 8.84%. North America accounted for 38.10% of the market revenue in 2025.
AI Analysis | Feedback
Haemonetics (HAE) anticipates several key drivers to fuel its revenue growth over the next two to three years:
- Plasma Segment Expansion and Innovation: Growth in the Plasma segment is expected to be a primary driver, propelled by the continued adoption and innovation of its NexSys PCS system, particularly with the proprietary Persona Technology. This technology is designed to enhance plasma yield, improve operational efficiency in collection centers, and elevate the donor experience. The company foresees sustained strong performance in its Plasma business, supported by increasing global demand for plasma collections.
- Hospital Segment Strength, particularly Blood Management Technologies: The Hospital business is projected to maintain robust growth, especially within its Blood Management Technologies portfolio. This includes the strong performance of TEG diagnostic systems and the increasing adoption of the heparinase neutralization cartridge in hemostasis management. Additionally, the VASCADE closure devices, including newer introductions like VASCADE MVP XL expanding into electrophysiology, are expected to continue contributing to revenue expansion within this segment.
- New Product Launches and Research & Development: Haemonetics is committed to significant investment in research and development to expand its product offerings. Key anticipated launches that are expected to drive future revenue include an advanced whole blood automation system, designed to streamline blood collection and processing, and the U.S. launch of PerQseal Elite. The company's focus on developing next-generation technologies and AI-driven analytics platforms underscores its innovation-led growth strategy.
- Geographical Market Expansion: The company is strategically targeting high-growth emerging markets for expansion, with a particular focus on the Asia-Pacific (APAC) region. This geographical diversification is a key initiative to broaden its customer base and generate additional revenue streams over the coming years.
AI Analysis | Feedback
Share Repurchases
- In April 2025, Haemonetics' Board of Directors authorized a new share repurchase program of up to $500 million of common stock over the next three years to offset the dilutive impact of employee equity grants.
- During fiscal year 2025, Haemonetics completed its prior $300 million share repurchase program, which included an accelerated share repurchase agreement for $150 million that resulted in the repurchase of approximately 2.4 million shares.
- As of November 2025, the company completed a $75 million buyback, repurchasing 1,430,579 shares (approximately 2.97% of outstanding stock) under the May 2025 authorization.
Share Issuance
- In May 2024, Haemonetics announced its intention to offer $525 million aggregate principal amount of Convertible Senior Notes due 2029 in a private offering, with an option for initial purchasers to acquire up to an additional $75 million. The proceeds are intended for capped call transactions, working capital, and general corporate purposes, including debt repayment.
- In March 2021, the company priced an offering of $435 million aggregate principal amount of 0.00% Convertible Senior Notes due 2026, which was an increase from the previously announced $425 million. An option for an additional $65 million principal amount was also granted.
- The total net proceeds from the sale of the 2026 Convertible Senior Notes were approximately $486.7 million.
Outbound Investments
- In January 2026, Haemonetics acquired Vivasure Medical Limited in a transaction valued up to €185 million (approximately $215 million) upon the completion of certain milestones. Haemonetics had previously made a strategic investment in Vivasure Medical in 2022, which included an option to acquire the company.
- In December 2023, Haemonetics completed the acquisition of OpSens Inc., a cardiology-focused medical device company, for approximately $255 million in an all-cash transaction. This acquisition expanded Haemonetics' presence in the interventional cardiology market.
- In April 2024, the company acquired Attune Medical for $160 million, adding an Esophageal Protection product line and expanding its Hospital segment.
Capital Expenditures
- Haemonetics' capital expenditures were $39.278 million in fiscal year 2025 and $38.125 million in fiscal year 2024.
- The company's capital allocation strategy prioritizes funding planned internal investments to support growth.
- Expected capital expenditures are estimated at $40 million for fiscal 2026, $41 million for fiscal 2027, and $42 million for fiscal 2028.
Peer Outperformance in Health Care Supplies
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.7% | 79.7% | 140.2% | CAH 411% · MCK 348% · COR 179% |
| Health Care Services | 20 | 20.0% | 41.9% | 9.5% | HIMS 302% · RDNT 143% · DGX 72% |
| Managed Health Care | 8 | 33.2% | -3.6% | 1.3% | OSCR 142% · HQY 64% · ELV 14% |
| Health Care Facilities | 24 | 11.9% | -3.3% | -15.7% | THC 289% · NHC 263% · ENSG 132% |
| Health Care Equipment | 51 | -2.3% | -9.2% | -18.9% | POCI 10738% · UFPT 396% · GKOS 288% |
| Health Care Supplies ← | 12 | 38.3% | -12.4% | -27.5% | LNTH 314% · HAE 81% · MMSI 31% |
| Pharmaceuticals | 63 | 3.1% | -1.7% | -31.9% | LQDA 2959% · INDV 1388% · ETON 1385% |
| Life Sciences Tools & Services | 108 | -8.4% | -32.7% | -70.6% | SNWV 1953% · ELMD 259% · MEDP 235% |
| Health Care Technology | 20 | -28.4% | -53.8% | -73.9% | SPOK 37% · HSTM -2% · VEEV -24% |
| Biotechnology | 365 | 6.6% | -27.4% | -77.2% | BRTX 106400% · DNTH 1803% · CELZ 1443% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 98.37 |
| Mkt Cap | 9.1 |
| Rev LTM | 6,815 |
| Op Inc LTM | 228 |
| FCF LTM | 552 |
| FCF 3Y Avg | 416 |
| CFO LTM | 824 |
| CFO 3Y Avg | 658 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.9% |
| Rev Chg 3Y Avg | 4.7% |
| Rev Chg Q | 5.5% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Inc Chg LTM | 10.3% |
| Op Inc Chg 3Y Avg | 39.6% |
| Op Mgn LTM | 13.6% |
| Op Mgn 3Y Avg | 12.0% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 15.5% |
| CFO/Rev 3Y Avg | 15.7% |
| FCF/Rev LTM | 10.4% |
| FCF/Rev 3Y Avg | 11.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 9.1 |
| P/S | 2.6 |
| P/Op Inc | 21.4 |
| P/EBIT | 24.5 |
| P/E | 36.9 |
| P/CFO | 15.7 |
| Total Yield | 3.1% |
| Dividend Yield | 0.7% |
| FCF Yield 3Y Avg | 4.8% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 14.5% |
| 3M Rtn | 32.7% |
| 6M Rtn | 21.6% |
| 12M Rtn | 35.1% |
| 3Y Rtn | 23.9% |
| 1M Excs Rtn | 13.6% |
| 3M Excs Rtn | 33.0% |
| 6M Excs Rtn | 9.2% |
| 12M Excs Rtn | 15.2% |
| 3Y Excs Rtn | -54.1% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Hospital | 588 | 564 | 456 | 382 | 322 |
| Plasma | 524 | 535 | 570 | 500 | 352 |
| Blood Center | 221 | 261 | 283 | 287 | 295 |
| Effect of exchange rates | 4 | ||||
| Service | 21 | ||||
| Total | 1,334 | 1,361 | 1,309 | 1,169 | 993 |
| $ Mil | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Plasma | 185 | 185 | 182 | 125 | 183 |
| Hospital | 104 | 89 | 52 | 29 | 130 |
| Blood Center | 50 | 53 | 42 | 64 | 137 |
| Remeasurement of contingent consideration | 2 | 23 | 0 | ||
| Restructuring and restructuring related costs | -3 | -21 | -24 | -12 | |
| Other | -8 | 2 | -15 | -14 | |
| Acquisition, integration and divestiture related costs | -14 | -23 | -11 | 0 | |
| Digital transformation costs | -22 | -20 | -16 | -5 | 0 |
| Amortization of acquired assets | -50 | -63 | -35 | -33 | -47 |
| Impairment of intangible assets | -87 | -2 | -10 | 0 | |
| Contingent Consideration | 0 | ||||
| Amortization of fair value inventory step-up | 0 | ||||
| Corporate expenses | -281 | ||||
| Effect of exchange rates | 19 | ||||
| Gains on divestiture and sale of assets | 10 | ||||
| Integration and transaction costs | -22 | ||||
| Litigation-related charges | -1 | ||||
| Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) costs | -11 | ||||
| Restructuring costs | -4 | ||||
| Restructuring related costs | -25 | ||||
| Write downs of certain in-process assets and PCS2 related charges | -6 | ||||
| Total | 157 | 222 | 165 | 156 | 81 |
Price Behavior
| Market Price | $104.65 | |
| Market Cap ($ Bil) | 4.8 | |
| First Trading Date | 05/10/1991 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $79.32 | $69.79 |
| DMA Trend | up | up |
| Distance from DMA | 31.9% | 50.0% |
| 3M | 1YR | |
| Volatility | 48.0% | 49.5% |
| Downside Capture | -91.63 | 11.38 |
| Upside Capture | 197.59 | 87.03 |
| Correlation (SPY) | 3.5% | 5.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.23 | -0.12 | 0.02 | 0.19 | 0.22 | 0.61 |
| Up Beta | -1.46 | -2.03 | -1.98 | -1.00 | -0.06 | 0.59 |
| Down Beta | -1.14 | -0.49 | -0.13 | -0.10 | -0.85 | 0.29 |
| Up Capture | 145% | 145% | 154% | 90% | 70% | 42% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 12 | 22 | 35 | 66 | 129 | 382 |
| Down Capture | -64% | -17% | -13% | 50% | 85% | 97% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 10 | 21 | 28 | 60 | 122 | 367 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HAE | |
|---|---|---|---|---|
| HAE | 95.3% | 49.5% | 1.49 | - |
| Sector ETF (XLV) | 26.3% | 15.5% | 1.31 | 24.7% |
| Equity (SPY) | 20.4% | 12.8% | 1.17 | 3.3% |
| Gold (GLD) | 29.8% | 28.5% | 0.91 | -5.2% |
| Commodities (DBC) | 40.2% | 20.2% | 1.56 | -9.1% |
| Real Estate (VNQ) | 13.1% | 13.9% | 0.65 | 11.9% |
| Bitcoin (BTCUSD) | -45.4% | 42.7% | -1.30 | -4.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HAE | |
|---|---|---|---|---|
| HAE | 13.0% | 40.7% | 0.41 | - |
| Sector ETF (XLV) | 6.6% | 15.0% | 0.25 | 32.4% |
| Equity (SPY) | 13.1% | 17.2% | 0.59 | 30.2% |
| Gold (GLD) | 19.8% | 18.6% | 0.87 | 0.3% |
| Commodities (DBC) | 9.8% | 19.6% | 0.39 | 3.0% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.02 | 28.9% |
| Bitcoin (BTCUSD) | 7.1% | 52.6% | 0.32 | 10.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HAE | |
|---|---|---|---|---|
| HAE | 11.6% | 40.2% | 0.41 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.51 | 34.6% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 36.3% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | -0.2% |
| Commodities (DBC) | 7.8% | 18.1% | 0.35 | 10.5% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 30.0% |
| Bitcoin (BTCUSD) | 59.9% | 66.0% | 1.00 | 11.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/18/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 1.7% | 9.3% | |
| 5/7/2026 | 3.2% | 8.2% | 35.3% |
| 2/5/2026 | -1.4% | -12.8% | -2.8% |
| 11/6/2025 | 32.3% | 44.2% | 64.1% |
| 8/7/2025 | -26.6% | -28.9% | -28.2% |
| 5/8/2025 | 5.9% | 6.8% | 9.7% |
| 2/6/2025 | -11.6% | -13.9% | -3.6% |
| 11/7/2024 | 10.7% | 17.4% | 3.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 15 |
| # Negative | 10 | 10 | 8 |
| Median Positive | 6.6% | 8.7% | 9.7% |
| Median Negative | -8.8% | -10.2% | -9.4% |
| Max Positive | 32.3% | 44.2% | 64.1% |
| Max Negative | -26.6% | -28.9% | -28.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 1.7% | 9.3% | |
| 5/7/2026 | 3.2% | 8.2% | 35.3% |
| 2/5/2026 | -1.4% | -12.8% | -2.8% |
| 11/6/2025 | 32.3% | 44.2% | 64.1% |
| 8/7/2025 | -26.6% | -28.9% | -28.2% |
| 5/8/2025 | 5.9% | 6.8% | 9.7% |
| 2/6/2025 | -11.6% | -13.9% | -3.6% |
| 11/7/2024 | 10.7% | 17.4% | 3.9% |
| 8/8/2024 | -10.8% | -14.6% | -14.6% |
| 5/9/2024 | -0.7% | 3.5% | -8.2% |
| 2/8/2024 | 1.3% | -7.6% | 3.2% |
| 11/2/2023 | -1.1% | -0.3% | -2.5% |
| 8/8/2023 | 1.5% | 4.7% | 0.1% |
| 5/11/2023 | 3.3% | 2.9% | 6.1% |
| 2/7/2023 | -5.9% | -7.0% | -10.5% |
| 11/7/2022 | 3.6% | -1.7% | 4.3% |
| 8/10/2022 | 8.9% | 12.9% | 11.6% |
| 5/10/2022 | 10.4% | 16.9% | 33.1% |
| 2/8/2022 | 16.2% | 23.8% | 26.5% |
| 11/9/2021 | -15.4% | -18.6% | -22.0% |
| 8/11/2021 | 7.3% | 2.6% | 13.7% |
| 5/13/2021 | -13.4% | -5.5% | 0.4% |
| 2/2/2021 | 13.0% | 21.3% | 6.3% |
| 11/4/2020 | -6.8% | 7.0% | 10.4% |
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 15 |
| # Negative | 10 | 10 | 8 |
| Median Positive | 6.6% | 8.7% | 9.7% |
| Median Negative | -8.8% | -10.2% | -9.4% |
| Max Positive | 32.3% | 44.2% | 64.1% |
| Max Negative | -26.6% | -28.9% | -28.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/20/2026 | 10-K |
| 12/31/2025 | 02/05/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/21/2025 | 10-K |
| 12/31/2024 | 02/06/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-K |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-K |
| 12/31/2022 | 02/07/2023 | 10-Q |
| 09/30/2022 | 11/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/20/2026 | 10-K |
| 12/31/2025 | 02/05/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/21/2025 | 10-K |
| 12/31/2024 | 02/06/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-K |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-K |
| 12/31/2022 | 02/07/2023 | 10-Q |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/25/2022 | 10-K |
| 12/31/2021 | 02/08/2022 | 10-Q |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/26/2021 | 10-K |
| 12/31/2020 | 02/02/2021 | 10-Q |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/04/2020 | 10-Q |
| 03/31/2020 | 05/20/2020 | 10-K |
| 12/31/2019 | 02/04/2020 | 10-Q |
| 09/30/2019 | 11/01/2019 | 10-Q |
Recent Forward Guidance
Updated 8/7/2026Latest: Q1 2027 Earnings Reported 8/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Reported Revenue Growth | 5.0% | 6.5% | 8.0% | 1.0% | Raised | Guidance: 5.5% for 2027 | |
| 2027 Organic Revenue Growth | 4.0% | 5.5% | 7.0% | 1.0% | Raised | Guidance: 4.5% for 2027 | |
| 2027 Free Cash Flow Conversion | 0.8 | 0.0% | Affirmed | Guidance: 0.8 for 2027 | |||
Prior: Q4 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Reported Revenue Growth | 4.0% | 5.5% | 7.0% | ||||
| 2027 Organic Revenue Growth | 3.0% | 4.5% | 6.0% | ||||
| 2027 Adjusted Operating Margin Change | 0.5% | 0.75% | 1.0% | ||||
| 2027 Free Cash Flow Conversion | 0.8 | ||||||
Q3 2026 Earnings Reported 2/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted Operating Margin | 26.0% | 26.5% | 27.0% | 0.0% | Affirmed | Guidance: 26.5% for 2026 | |
| 2026 Adjusted EPS | 4.9 | 4.95 | 5 | 1.0% | Raised | Guidance: 4.9 for 2026 | |
| 2026 Free Cash Flow | 200.00 Mil | 210.00 Mil | 220.00 Mil | 10.5% | Raised | Guidance: 190.00 Mil for 2026 | |
| 2026 Free Cash Flow to Adjusted Net Income | 0.8 | ||||||
Q2 2026 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue Growth | -4.0% | -2.5% | -1.0% | ||||
| 2026 Adjusted Operating Margin | 26.0% | 26.5% | 27.0% | 0 | Affirmed | Guidance: 26.5% for 2026 | |
| 2026 Adjusted EPS | 4.8 | 4.9 | 5 | 1.0% | Raised | Guidance: 4.85 for 2026 | |
| 2026 Free Cash Flow | 170.00 Mil | 190.00 Mil | 210.00 Mil | 5.6% | Raised | Guidance: 180.00 Mil for 2026 | |
Insider Activity
Updated 7/28/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kroll, Mark W | Direct | Buy | 11122025 | 70.56 | 1,400 | 98,784 | 1,746,854 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kroll, Mark W | Direct | Buy | 11122025 | 70.56 | 1,400 | 98,784 | 1,746,854 | Form |
Investor Activity (13F)
Updated Aug 19, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.